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While the physiological benefits of the fibroblast
growth factor 21 (FGF21) hepatokine are documented
in response to fasting, little information is available on
Fgf21 regulation in a glucose-overload context.
We report that peroxisome-proliferator-activated
receptor a (PPARa), a nuclear receptor of the fasting
response, is required with the carbohydrate-sensitive
transcription factor carbohydrate-responsive ele-
ment-binding protein (ChREBP) to balance FGF21
glucose response. Microarray analysis indicated that
only a few hepatic genes respond to fasting and
glucose similarly to Fgf21. Glucose-challenged
Chrebp/mice exhibit a marked reduction in FGF21
production, a decrease that was rescued by re-
expression of an active ChREBP isoform in the liver
of Chrebp/ mice. Unexpectedly, carbohydrate
challenge of hepatic Ppara knockout mice also
demonstratedaPPARa-dependentglucose response
for Fgf21 that was associated with an increased
sucrose preference. This blunted response was due
to decreased Fgf21 promoter accessibility and dimin-
ished ChREBP binding onto Fgf21 carbohydrate-
responsive element (ChoRE) in hepatocytes lacking
PPARa. Our study reports that PPARa is required
for the ChREBP-induced glucose response of FGF21.
INTRODUCTION
The liver is central for the regulation of energy homeostasis,
controlling several biochemical pathways important for meta-Ce
This is an open access article under the CC BY-Nbolism of lipids, carbohydrates, proteins, bile synthesis, and
detoxification of drugs and toxins. The liver also controls endo-
crine responses through the production of hepatokines. These
proteins secreted by the hepatocytes act as hormones, and
several hepatokines are considered promising leads for meta-
bolic therapy development (Iroz et al., 2015). Among them,
fibroblast growth factor 21 (FGF21) has emerged as an inter-
esting target (Kharitonenkov and Adams, 2013). Originally
targeted for its glucose-lowering properties in rodents and
primates (Berglund et al., 2009; Fisher et al., 2011; Kharitonen-
kov et al., 2007), FGF21 is also able to improve insulin sensi-
tivity and lipid homeostasis and induce weight loss (Coskun
et al., 2008; Markan et al., 2014).
Fgf21 is a direct target of the nuclear receptor peroxisome-
proliferator-activated receptor a (PPARa) in response to fasting
(Badman et al., 2007; Lunda˚sen et al., 2007). Activated by free
fatty acids derived from lipolysis (Jaeger et al., 2015; Montagner
et al., 2016), PPARa is essential to liver health, as its deletion
promotes the development of non-alcoholic fatty liver disease
(NAFLD) and hypercholesterolemia during aging (Montagner
et al., 2016). The beneficial role of PPARa in response to dyslipi-
demia is thought to be mediated, at least in part, through FGF21
(Ong et al., 2012). Indeed, anti-diabetic therapies and PPARa
agonists (fenofibrate or Wy-14653) significantly induce liver-
derived FGF21 in both mouse and human plasma (Christodou-
lides et al., 2009; Ga¨lman et al., 2008; Lunda˚sen et al., 2007).
Hepatocyte PPARa plays an essential role during fasting,
which triggers transcriptional regulation for the maintenance of
glycemia and ketogenesis through fatty acid catabolism for
use as an alternative energy source (Goldstein and Hager,
2015). In agreement, PPARa-deficient mice exhibit impaired
fatty acid oxidation and ketogenesis that promotes hepatic stea-
tosis during fasting (Kersten et al., 1999; Kroetz et al., 1998;
Leone et al., 1999; Montagner et al., 2016).ll Reports 21, 403–416, October 10, 2017 ª 2017 The Authors. 403
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Recent work reported that FGF21 is also activated in response
to glucose and fructose in rodents and humans (Herman et al.,
2012; Iizuka et al., 2009; Sa´nchez et al., 2009; Uebanso et al.,
2011). Enriched in liver, the transcription factor carbohydrate-
responsive element-binding protein (ChREBP) mediates the
response to dietary carbohydrates (Abdul-Wahed et al., 2017).
A physiological role for the ChREBP-FGF21 axis was revealed
in experiments showing that in response to sugar consumption,
ChREBP-enhanced FGF21 secretion from the liver blocked
sugar-seeking behavior in mice and primates by targeting the
paraventricular nucleus of the hypothalamus (Talukdar et al.,
2016; von Holstein-Rathlou et al., 2016). The ChREBP protein
contains a low-glucose inhibitory domain (LID) and a glucose
responsive activation conserved element (GRACE) located in
its N terminus (Li et al., 2006). Activation of GRACE by glucose
promotes ChREBP transcriptional activity and binding to the
carbohydrate-responsive element (ChoRE) of its target genes,
including L-pyruvate kinase (Lpk), a rate-limiting enzyme in
glycolysis, fatty acid synthase (Fas), and steroyl CoA desaturase
(Scd1), key enzymes of de novo lipogenesis (Kawaguchi et al.,
2001). Another isoform of Chrebp, Chrebpb, originating from
an alternative promoter, was identified in adipose tissue and liver
(Herman et al., 2012). This alternative splicing results in a consti-
tutively active ChREBP isoform lacking the LID, a domain asso-
ciated with inhibition of ChREBP activity (Herman et al., 2012).
Understanding the regulation of FGF21 is currently a research
focal point. Through the use ofChrebp knockout mice, we report
here that ChREBP is required for the expression and secretion of
hepatic FGF21 in response to carbohydrate intake. Unexpect-
edly, studies in hepatocyte-specific Ppara knockout mice reveal
a physiological role for PPARa in the context of glucose chal-
lenge, as ChREBP is unable to induce Fgf21 in the absence of
hepatic PPARa. Altogether, our results suggest that FGF21’s
glucose-mediated response is dependent on both ChREBP
and PPARa.
RESULTS
FGF21 Is Induced by Both Fasting and Glucose
Challenge
To characterize gene expression during fasting and a glucose
challenge, a microarray analysis was conducted using liver sam-
ples fromwild-typemice (Figure 1). Genes sensitive to glucose or
fasting that were markedly different from the fed group were
incorporated into a heatmap (Figure 1A). 67 genes were signifi-
cantly induced by glucose in comparison to fed conditions
(cluster 1), and 675 genes were significantly upregulated be-
tween fed and fasted groups (cluster 6). Gene ontology analysis
revealed that pathways identified as specifically impacted by
glucose and not by fasting are involved in pyruvate and insulin-
sensitive metabolism (Figure 1B). Gene ontology revealed that
pathways specifically sensitive to fasting, but not to glucose,
are involved in PPAR signaling (Figure 1C). Interestingly, among
the top genes upregulated by glucose and fasting (Figure S1A),
only 3 genes (Fgf21, Fut1, and Atf5) were significantly upregu-
lated (log fold change [FC] > 1; p % 0.01) as compared to fed
conditions (Figure 1D). When the stringency of the selection
was increased to a log FC > 2 (Figure 1E), Fgf21 was left to be404 Cell Reports 21, 403–416, October 10, 2017the sole gene upregulated by both fasting and glucose challenge
(log FC= 3.9 and log FC= 3.7, respectively (p% 0.01) (Figure 1E).
qPCR analysis confirmed that Fgf21 expression was significantly
upregulated by fasting and glucose compared to fed conditions
(Figure 1F). The glucose effect was validated through analysis of
Chrebp, Chrebpb, and Lpk gene expression, while the effect of
fasting was assessed bymeasuring the expression of two typical
PPARa targets, Cyp4a10 and Vnn1 (Figure 1F).
ChREBP Is Necessary for Glucose-Mediated Expression
and Secretion of Hepatic FGF21
To address the importance of ChREBP in the Fgf21 glucose
response, experiments were first performed in mouse hepato-
cytes from wild-type mice (Figure 2). We observed that Fgf21
expression was induced by elevated glucose concentrations
and paralleled with Chrebp, Chrebpb, and target gene expres-
sion (Figure 2A). ChREBP recruitment onto the Fgf21 and
Lpk promoters significantly increased under high glucose con-
centrations (25 mM) (Figure 2B). This stimulatory effect of
glucose was specific and not linked to an osmotic shock, since
Fgf21 expression was not induced in response to mannitol
(Figure S2). To determine whether ChREBP is mandatory for
upregulation of FGF21 in response to glucose, experiments
were completed in hepatocytes lacking ChREBP (Chrebp/)
(Figures 2C–2E). Mice lacking exons 9–15 of the Chrebp gene
were generated through homologous recombination (Figure S3).
The absence of the ChREBP protein (a isoform, 94 kDa) was
validated in Chrebp/ hepatocytes by western blot analysis
(Figure 2C). Under these conditions, the ChREBPb protein
(72 kDa) could not be detected (data not shown). Similarly to
Chrebp, Chrebpb, and the ChREBP and ChREBPb target genes
Lpk and Scd1, Fgf21 robustly responded to 25 mM glucose
stimulation in wild-type hepatocytes, but this response was
blunted in Chrebp/ hepatocytes (Figure 2D). In addition, no
increase in FGF21 in culture medium was detected when
Chrebp/ hepatocytes were cultured in 25 mM glucose
(Figure 2E). Of note, basal FGF21 production (5 mM glucose)
was also significantly decreased in culture medium from
Chrebp/ hepatocytes (Figure 2E). These findings indicate
that ChREBP is mandatory for the glucose-mediated expression
and secretion of FGF21 by hepatocytes.
Liver-Specific ChREBP Expression Rescues FGF21
Plasma Concentrations in ChREBP Knockout Mice
Wenext performed glucose challenge experiments in vivo. 10- to
12-week-old Chrebp+/+ and Chrebp/ male mice were given
24-hr access to a bottle of glucose-free water (fed) or a bottle
containing 20% glucose (glucose challenge) (Figure 3). A signif-
icant elevation in blood glucose was observed in glucose-
challenged Chrebp/mice compared to Chrebp+/+ mice under
the same conditions (Figure 3A). A trend toward higher insulin
concentrations was observed in Chrebp/ mice compared to
controls (under fed and glucose conditions), but this difference
did not reach statistical significance (Figure 3B). Glucose
challenge raised ChREBP protein content in liver of Chrebp+/+
mice (Figure 3C). A significant stimulation in hepatic tri-
glyceride (TG) concentrations was also observed in glucose-
challenged Chrebp+/+ mice, but not Chrebp/mice (Figure 3D).
Figure 1. FGF21 Is Highly Induced by Both Fasting and Glucose Challenge
Wild-type C57BL/6J 10-week-old male mice were fed ad libitum, fasted for 24 hr, or fed for 24 hr a standard diet with addition of 20% glucose in drinking
water (glucose challenge). Mice were killed at ZT14 (14 hr after the start of light period in the animal housing unit). Transcriptomic analysis was performed on livers
(n = 6 per condition) using gene expression microarray.
(A) Heatmap of differentially expressed probes (false discovery rate [FDR] < 5%).
(B and C) KEGG categories corresponding to functions impacted by glucose (B) and fasting (C).
(D) Venn diagram presenting the overlap between glucose- and fasting-induced gene expression (log FC > 1; adjusted p < 0.01).
(E) Venn diagram presenting the overlap between glucose- and fasting-induced gene expression (log FC > 2; adjusted p < 0.01).
(F) Gene expression determined by qPCR. Data are expressed as means ± SEM, n = 6 individual mice per group. Significance is based on two-way ANOVA
followed by a Bonferroni post hoc test. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 2. ChREBP Is Necessary for Glucose-Mediated Expression and Secretion of FGF21 In Vitro
(A and B) Hepatocytes prepared from male C57BL/6J mouse livers were stimulated 1 day after platting for 24 hr with medium containing 5, 10, 15, 20, 25, or
30mMglucose. (A) qPCR analysis of Fgf21,Chrebp, Chrebpb, Lpk, and Scd1 gene expression. Data are presented asmeans ± SEM from 4 independent cultures
done in triplicate. Significance is based on two-way ANOVA followed by a Bonferroni post hoc test (*p < 0.05; **p < 0.01; ***p < 0.001). (B) ChIP analysis for
ChREBP binding on the Fgf21 and Lpk ChoRE followed by qPCR in mouse hepatocytes challenged with 5 or 25 mM glucose for 24 hr. Data are expressed as
means ± SEM (n = 3). Significance is based on Student’s t test followed by Mann-Whitney post hoc test (*p < 0.05).
(C–E) Primary hepatocytes from femaleChrebp/ andChrebp+/+ littermates were stimulated 1 day after platting for 24 hr with cell culturemedium containing 5 or
25 mM glucose. (C) Western blot analysis of protein from whole hepatocyte lysate. Two representative samples are presented. b actin was used as loading
control. (D) Gene expression determined by qPCR. (E) ELISA quantification of FGF21 protein in medium collected at the end of glucose stimulation.
Data are presented as means ± SEM from 4 independent cultures in triplicate. Significance is based on two-way ANOVA followed by a Bonferroni post hoc
test (*p < 0.05; **p < 0.01; ***p < 0.001).A significant increase inChrebp,Chrebpb, Lpk, and Scd1mRNA
levels was observed in liver of glucose-challenged Chrebp+/+
mice compared to fed mice from the same genotype (Figure 3E).
Fgf21 mRNA and plasmatic FGF21 protein concentrations
markedly increased in glucose-challenged Chrebp+/+ mice.
While a residual (nonsignificant) glucose effect was observed
in Chrebp/ mice, this response was significantly reduced
compared to Chrebp+/+ mice (Figures 3F and 3G), despite
elevated blood glucose levels (Figure 3A). These results show
that ChREBP is required for the in vivo glucose-mediated induc-
tion of Fgf21.
We next addressed whether liver-specific re-expression of
Chrebp in a context of global ChREBP deficiency could rescue
FGF21 production. Chrebp+/+ and Chrebp/ adult mice were
injected with an adenovirus vehicle containing the GFP protein
or a truncated isoform of ChREBP lacking the LID domain (Li406 Cell Reports 21, 403–416, October 10, 2017et al., 2006) corresponding to a constitutively active ChREBP
isoform (ChREBPCA). Mice received a 20% glucose solution
for 24 hr before sacrifice (Figures 3H–3K). Blood glucose
concentrations were higher in GFP-ChREBP/ mice than in
GFP-ChREBP+/+ mice and were rescued to basal values
when ChREBPCA was injected into Chrebp/ mice (Figure 3H).
Western blot analysis confirmed the absence of native ChREBP
protein (94 kDa) but the presence of ChREBPCA (72 kDa) in
Chrebp/mice injectedwith ChREBPCA (Figure 3I). Importantly,
ChREBPCA rescued the circulating level of FGF21 (Figure 3J).
This correlates with the effect of ChREBPCA on the hepatic
expression of Chrebp, Chrebpb, and their targets, Lpk, Scd1,
and Fgf21 mRNA (Figure 3K). Altogether, we report that
ChREBPCA administration rescued ChREBP activity in the liver
of Chrebp/ mice and was sufficient to restore FGF21 gene
expression and production.
Figure 3. FGF21 Is Unable to Respond to a Glucose Challenge without ChREBP
(A–G) Adult maleChrebp/ andChrebp+/+ littermates were allowed access to a 20% glucose drinking water solution and standard chow diet ad libitum for 18 hr.
Fed mice received drinking water from the same water source used to make the glucose solution. (A) Blood glucose (mg/dl) recovered at the time of harvest from
tail snip. (B) Insulin concentrations (ng/ml). (C) Western blot analysis of protein from whole liver lysate. b actin was used as loading control. Three representative
samples are presented. (D) Hepatic triglyceride (TG) concentrations. RelativeChrebp,Chrebpb, Lpk, andScd1 gene expression (E) and Fgf21 (F) gene expression
determined by qPCR. (G) ELISA quantification of FGF21 protein (ng/mL) in plasma. Data are presented as means ± SEM from 6 to 8 individual mice. Significance
is based on two-way ANOVA followed by a Bonferroni post hoc test (*p < 0.05; **p < 0.01; ***p < 0.001; nd, not detectable).
(H–J) Adult male Chrebp+/+ and Chrebp/mice were injected intravenously with a single dose of 33 109 pfu GFP or ChREBPCA adenovirus on day 1. Four days
later, analyses were performed. (H) Blood glucose (mg/dl) recovered at the time of harvest from tail snip. (I) Western blot analysis of protein extracted from whole
liver lysate. b actin was used as loading control. Three representative samples are presented. (J) ELISA quantification of FGF21 protein (ng/ml) in plasma.
(K) Relative expression of hepatic genes determined by qPCR.
Data are presented as means ± SEM from 8 to 12 individual mice. Significance is based on two-way ANOVA followed by a Bonferroni post hoc test (*p < 0.05;
**p < 0.01; ***p < 0.001; nd, not detectable).Glucose Stimulation or ChREBP Overexpression Is Not
Efficient to Induce FGF21 Expression or Secretion in the
Absence of Hepatic PPARa
Since the Fgf21 promoter contains overlapping peroxisome
proliferator response element (PPRE) and ChoRE units
(88 to 54 bp) (Girer et al., 2016; Uebanso et al., 2011), we
investigated whether PPARa could impact the glucose response
of Fgf21 mediated by Chrebp. Primary hepatocytes from
liver-specific Ppara knockout mice (Pparahep/) and their
littermates, Pparahep +/+ mice (Montagner et al., 2016), were
stimulated by glucose in a dose-dependent manner (Fig-ure 4). A similar glucose-mediated induction of Chrebp,
Chrebpb, Lpk, and Scd1 mRNA was observed in hepatocytes
from Pparahep +/+ and Pparahep / mice (Figure 4A). Although
a residual glucose effect was observed for Fgf21 expression in
Pppaahep / mice hepatocytes, this response was reduced
compared to Pparahep+/+ mice (Figure 4B). Importantly, FGF21
production in response to glucose was reduced by 60% in
culture medium from Pppaahep/ hepatocytes compared to
controls (Figure 4C). This profile was specific to Fgf21, since
the expression of other typical PPARa targets (Cyp4a10,
Cyp4a14, or Vnn1) was not induced by glucose (Figure S4). WeCell Reports 21, 403–416, October 10, 2017 407
Figure 4. Fgf21 Is Not Efficiently Induced by Glucose or by ChREBP Overexpression in the Absence of Liver PPARa
(A–C) Primary hepatocytes derived from adult male Pparahep+/+ or Pparahep/ mice were incubated 1 day after platting for 24 hr with medium containing
5, 10, 15, 20, 25, or 30 mM glucose. Relative Chrebp, Chrebpb, Lpk, and Scd1 gene expression (A) and Fgf21 gene expression (B) was determined by qPCR.
(C) ELISA quantification of FGF21 protein (ng/ml) in medium collected at end of glucose stimulation. Figures are presented as means ± SEM from 4 inde-
pendent cultures completed in duplicate. Significance is based on two-way ANOVA followed by a Bonferroni post hoc test (*p < 0.05; **p < 0.01; ***p < 0.001;
nd, not detectable).
(D–F) Primary hepatocytes derived from adult male mice Pparahep+/+ or Pparahep/ were incubated 6 hr after platting with 3 3 109 pfu GFP or
ChREBPCA adenovirus at a glucose concentration of 5 mM for 24 hr. Relative Chrebp, Chrebpb, Lpk, and Scd1 expression (D) and of Fgf21 expression (E) was
determined by qPCR. (F) ELISA quantification of FGF21 protein (in ng/ml) in medium collected at end of adenoviral treatment.
Data are presented as means ± SEM from 4 independent cultures completed in duplicate. Significance is based on two-way ANOVA followed by a Bonferroni
post hoc test (*p < 0.05; **p < 0.01; ***p < 0.001).
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next addressed whether Fgf21 could be rescued by Chrebp
overexpression in the context of Ppara deficiency. Hepatocytes
from Pparahep+/+ and Pppaahep / mice were infected with
the constitutive active form of ChREBP (ChREBPCA) for 24 hr.
The expression of Chrebp and Chrebpb was significantly
increased in response to ChREBPCA in both Ppara hep+/+ and
Pppaahep / hepatocytes, and as a result, Lpk and Scd1
mRNA expression was stimulated compared to GFP conditions
(Figure 4D). However, while Chrebp overexpression led to a
50-fold increase in Fgf21 expression in Pparahep+/+ hepatocytes,
it failed to significantly induce Fgf21 expression in Pppaahep /
hepatocytes (Figure 4E). FGF21 measured in the medium of cell
culture confirmed the Fgf21mRNAexpression profile (Figure 4F).
These results suggest that neither glucose nor ChREBP over-
expression is efficient in inducing Fgf21 gene expression or
protein production in the absence of PPARa in hepatocytes.
FGF21 Synergistically Responds to Glucose and a
Pharmacological PPARa Activator in Both Mouse and
Human Hepatocytes
To determine whether ChREBP and PPARa act in synergy to
regulate Fgf21 gene expression, mouse and human hepatocytes
were stimulated for 24 hr with low (5 mM) or high glucose
concentrations (25 mM) in the presence of the PPARa agonist
Wy-14643 (Figure S5). Expression of Chrebp and Chrebpb
mRNA confirmed a positive glucose response in both mouse
and human hepatocytes (Figures S5A and S5B). Activation of
PPARa by Wy-14643 was validated by a significant upregulation
in Acox1 expression, a PPARa target gene (Figures S5C and
S5D). Fgf21mRNA levels were drastically increased when hepa-
tocytes (mouse and human) were incubated in the combined
presence of high glucose (25 mM) and Wy-14643 (Figures S5E
and S5F). Altogether, these results show that ChREBP and
PPARa can act synergistically to induce Fgf21 in mouse and in
human liver cells.
Hepatocyte PPARa Is Required for the Effect of Glucose
on FGF21 In Vivo
To investigate whether PPARa is involved in the glucose-
mediated induction of Fgf21 in vivo, glucose challenge experi-
ments were performed in 10- to 12-week-old Pparahep+/+ and
Ppara hep/ mice. Three nutritional conditions were assigned
to both genotypes: (1) mice fasted 24 hr with free access towater
(fasted), (2) mice fed ad libitum with access to standard chow
diet and free access to water (fed), and (3) mice fed ad libitum
with access to standard chow diet and a 20% glucose solution
in water (glucose challenge) (Figure 5). Chrebp, Chrebpb,
and their target genes (Lpk and Scd1) were induced in
a similar manner in the liver of Ppara hep+/+ and Pparahep/
mice when challenged by glucose (Figure 5A). In contrast, the
glucose-mediated induction of Fgf21 (compared to the fed state)
was significantly reduced in the absence of PPARa (Figure 5A).
FGF21 in the circulationmatched hepaticmRNA levels, revealing
an upregulation of FGF21 in the plasma of Ppara hep+/+ that was
significantly reduced in glucose-challenged Pparahep/ mice
(Figure 5B). As expected, loss of PPARa markedly impacted
the fasting response of FGF21 (Figure 5A-B). Because the
Fgf21 promoter contains overlapping PPRE and ChoRE units(Figure 5C), we investigated whether lack of PPARa could impair
ChREBP binding in response to glucose in vivo. When primers
amplifying both ChoRE and PPRE were used (Figure 5C), a
significant enrichment in PPARa binding within the proximal
region of the Fgf21 promoter in liver of Ppara hep+/+ mice was
observed (Figure 5D). While PPARa binding was elevated under
fasting conditions, a significant PPARa recruitment onto the
proximal region of the Fgf21 promoter was detected under
both fed and glucose-challenge conditions (Figure 5D).
Surprisingly, in liver of glucose challenged Ppara hep/ mice,
recruitment of ChREBP on the Fgf21 promoter ChoRE was
significantly reduced (Figure 5D). Interestingly, a significant
decrease in RNA polymerase II (Pol II) recruitment and histone
H3 lysine 9 acetylation (H3K9ac), a histone mark related to
transcriptional activation, was observed in parallel in the liver
of these mice (Figure 5D). In contrast, ChREBP recruitment on
the Lpk ChoRE was similar in glucose-challenged Pparahep+/+
and Pparahep / mice (Figure 5E). The presence of Pol II on
the Lpk promoter (Figure 5E) was significantly elevated in
response to glucose in liver of mice from both genotypes and
correlated with Lpk mRNA expression (Figure 5A). Altogether,
our results show that the absence of PPARa impairs the binding
of ChREBP to its ChoRE and the subsequent glucose-mediated
induction of Fgf21. Surprisingly, significant ChREBP recruitment
was also detected on the Fgf21 ChoRE under fasting conditions
(Figure 5D). Further analysis will be required to determine
whether ChREBP interferes with the fasting-mediated induction
of Fgf21 expression in the liver, as suggested in a recent
report showing that liver-specific Chrebp knockout mice have
decreased Fgf21 expression compared to controls (Jois et al.,
2017).
Fgf21 Promoter Accessibility Is Reduced in the Absence
of PPARa
To provide insights into the mechanisms by which PPARa
affects ChREBP binding onto the Fgf21 promoter in response
to glucose, a series of experiments were conducted in vitro
(Figure 6). First, we performed formaldehyde-assisted isolation
of regulatory elements (FAIRE)-qPCR analysis (Simon et al.,
2012) to determine whether ChREBP accessibility to the Fgf21
promoter could be altered in the absence of PPARa (Figure 6A).
We observed that while Fgf21 ChoRE promoter accessibility
tended to increase in response to high glucose concentrations
in Ppara hep+/+ hepatocytes, it failed to increase in Ppara hep/
hepatocytes (Figure 6A). To get insight into the molecular mech-
anisms involved, we hypothesized that PPARa could affect
ChoRE accessibility through epigenetic processes and tested
whether a pan-histone deacetylase (pan-HDAC) inhibitor (Imai
et al., 2016) could increase Fgf21 promoter accessibility.
Treatment of hepatocytes with a HDAC inhibitor further
enhanced the difference observed in Fgf21 accessibility be-
tween Pparahep+/+ and Pparahep/ hepatocytes (Figure 6A),
which correlated with a potentiated effect of glucose on Fgf21
expression (Figure 6B). While no significant change in Fgf21
promoter accessibility was observed in Pparahep / hepato-
cytes treated with the HDAC inhibitor (Figure 6A), a modest but
significant effect was observed for Fgf21mRNA levels measured
under these conditions. However, treatment failed to fully rescue
Fgf21 gene expression to control levels (Figure 6B). These dataCell Reports 21, 403–416, October 10, 2017 409
Figure 5. PPARa Is Required for the Glucose-
Dependent Expression and Secretion of
FGF21 by the Liver
Male Pparahep+/+ or Pparahep/mice were assigned
one of three treatment groups: (1) fasted 24 hr with
free access to drinking water (fasted), (2) fed ad
libitum with free access to drinking water (fed), or (3)
fed ad libitum with access to a 20% glucose drinking
water solution for 24 hr (glucose challenge).
(A) Relative gene expression of Chrebp, Chrebpb,
Lpk, Scd1, and Fgf21 was determined by qPCR.
Data are expressed as means ± SEM (n = 6 individual
mice per group). Significance is based on two-way
ANOVA followed by Bonferroni post hoc test (fasting
or glucose versus fed; #p % 0.05; ##p % 0.01;
###p % 0.001). Significance of the effect of geno-
type is based two-way ANOVA followed by Bonfer-
roni post hoc test (Pparahep/ versus Pparahep +/+;
*p% 0.05; **p% 0.01; ***p% 0.001).
(B) ELISA quantification of FGF21 in plasma. Data are
expressed as means ± SEM from n = 6 individual
mice per group. Significance of the effect of fasting
or glucose challenge is based on two-way ANOVA
followed by post hoc test (fasting or glucose versus
fed; #p % 0.05; ##p % 0.01; ###p % 0.001).
Significance of the effect of genotype is based
on two-way ANOVA followed by Bonferroni post
hoc test (Pparahep/ versus Pparahep +/+; *p% 0.05;
**p% 0.01; ***p% 0.001).
(C) Fgf21 promoter sequence from the transcription
start site to 184 bp. The PPARa binding site (PPRE)
is indicated in gray. The ChREBP binding site
(ChoRE) is indicated in yellow. Primers used for ChIP
analysis are indicated on the sequence.
(D) ChIP analysis followed by qPCR of whole mouse
liver tissue. Immunoprecipitation (IP) was conducted
with PPARa, ChREBP, H3K9ac, and RNA Pol II
antibodies. The DNA region of the Fgf21 promoter
was amplified using the primers indicated in (C).
(E) ChIP analysis followed by qPCR of whole mouse
liver tissue. IP were conducted with ChREBP and
RNAPol II antibodies. Data are expressed asmeans±
SEM from n = 3 individual mice per group. Signifi-
cance is based on two-way ANOVA followed by
Bonferroni post hoc test (**p% 0.01; ***p% 0.001).suggest that Fgf21 promoter accessibility at theChoRE is altered
in the absence of PPARa by a mechanism that may partly rely on
histone acetylation. To determine whether the potentiating effect
of the HDAC inhibitor on glucose-induced Fgf21 expression was
due to enhanced ChREBP activity, experiments were performed
in Chrebp+/+ and Chrebp/ hepatocytes (Figure 6C). Similar to
what was observed in Pparahep+/+ hepatocytes (Figure 6B), the
effect of glucose (25 mM) on Fgf21 expression was increased
when Chrebp+/+ hepatocytes were treated with the HDAC inhib-
itor (Figure 6C). Chrebp, Chrebpb, and Lpk followed a similar
trend, with a significant effect observed for Chrebp (Figure 6C).
Importantly, the potentiated effect of the HDAC inhibitor on
Fgf21 expression was lost inChrebp/ hepatocytes (Figure 6C),410 Cell Reports 21, 403–416, October 10, 2017indicating a dependence on ChREBP
activity. Altogether, our results suggest
that PPARa is essential to allow ChREBPto gain access to the promoter of Fgf21. Moreover, our data
show that the use of HDAC inhibitors enhances the ChREBP-
dependent effect of glucose on Fgf21 but cannot fully rescue
the effect of PPARa deficiency.
Sucrose Intake Is Increased in Mice Lacking PPARa in
the Liver
Finally, we determined whether the decrease in circulating
FGF21 observed in glucose-challenged Ppara hep/ mice (Fig-
ure 5B) paralleled with an increase in sucrose preference,
since it was recently demonstrated that FGF21’s action on the
paraventricular nucleus of the hypothalamus blocks sugar-
seeking behavior and sugar intake in mice (Talukdar et al.,
2016; von Holstein-Rathlou et al., 2016). First, we observed
Figure 6. Fgf21 Promoter Accessibility Is Reduced in the Absence of PPARa
(A and B) Primary hepatocytes derived from adult Pparahep+/+ or Pparahep/mice were treated with 10 mM of the HADC inhibitor LBH589 or DMSO as a control
for 24 hr in the presence of 5 or 25mMglucose. (A) FAIRE-qPCRwas performed as described in Experimental Procedures. (B) Fgf21 gene expression determined
by qPCR. Data are presented as means ± SEM from 4 independent cultures performed in duplicate. Significance is based on two-way ANOVA followed by
Bonferroni post hoc test (*p % 0.05; **p % 0.01; ***p % 0.001).
(C) Primary hepatocyte derived from adultChrebp+/+ orChrebp/mice were treated with 10 mMof the HADC inhibitor LBH589 or with DMSO as control for 24 hr
in the presence of medium containing 5 or 25 mM glucose. Relative gene expression of Chrebp, Chrebpb, Lpk, and Fgf21 was determined by qPCR.
Data are presented as means ± SEM from 4 independent cultures performed in duplicate. Significance is based on two-way ANOVA followed by Bonferroni post
hoc test (*p% 0.05; **p% 0.01; ***p% 0.001).that there was no change in body weight or food or water intake
in Ppara hep/ compared to Ppara hep+/+ mice fed with standard
chow (Figures 7A–7C). Sucrose preference was then evaluated
by giving Ppara hep+/+ and Ppara hep+/+ littermates matched for
age and body weight free choice between a bottle containing
a 10% sucrose solution and water (Figure 7D). Consumption,
which was measured daily for 3 days, demonstrated that
Ppara hep/ mice consumed 30% more sucrose solution
than Ppara hep+/+ mice, while the volume of water drunk re-
mained similar between genotypes (Figure 7E).DISCUSSION
The regulation of FGF21 in the liver is complex due to
the paradoxical regulation of this key hepatokine by fasting
and glucose signals. In the current study, we uncovered
a cross-talk between ChREBP and PPARa for the induction
of hepatic FGF21 in response to a glucose challenge.
The main finding of our study is that hepatic PPARa is
necessary for the glucose-mediated induction of Fgf21 by
ChREBP.Cell Reports 21, 403–416, October 10, 2017 411
Figure 7. Sucrose Intake Is Increased in Pparahep/ Mice
(A–C) Average body weight gain (A), food (B) and water (C) intake of age-matched Pparahep+/+ and Pparahep/ mice (n = 12/group) over 6 weeks.
(D) Average body weight of age-matched male Pparahep+/+ and Pparahep/ mice used for the sucrose preference test (n = 16/group).
(E) Pparahep+/+ and Pparahep/mice were given a 4-day adaptation period with two water bottles. A 10% sucrose solution was added to one of the water bottles
for 3 days following adaptation and intake of sucrose solution and water was recorded daily for 3 days. Data are presented as means ± SEM from 5 to 6 individual
mice. Significance is based on 2-way ANOVA followed by Bonferroni post hoc test (**p% 0.01).Key to b-oxidation and ketogenesis, FGF21 mobilizes energy
in the liver for peripheral use, protecting against dyslipidemia
and hepatosteatosis (Inagaki et al., 2007; Potthoff et al., 2009).
First described as a fasting hormone regulated by PPARa,
transcriptional regulation of Fgf21 in the context of excessive
blood glucose has only recently been explored (Talukdar
et al., 2016; vonHolstein-Rathlou et al., 2016), despite early iden-
tification of the glucose-sensing region, ChoRE, on the Fgf21
promoter in both mouse (74 to 52 bp) and human (380
to 366 bp) (Iizuka et al., 2009). Our experiments confirm that
FGF21 is significantly expressed and released by cultured
mouse and human hepatocytes in response to glucose upon
ChREBP binding to the ChoRE (Iizuka et al., 2009; Uebanso
et al., 2011). Our study demonstrates that deletion of ChREBP
blunts transcription and secretion of hepatic FGF21 in response
to glucose. Importantly, hepatic rescue of ChREBP in global
ChREBP knockout mice is sufficient to restore Fgf21 mRNA in
the liver and protein in circulation, demonstrating the specificity
of hepatic ChREBP activity on the induction of FGF21 in
response to a glucose challenge. Interestingly, ChREBP rescue
in the liver of Chrebp/ mice significantly normalized blood
glucose concentrations to control levels. This suggests that412 Cell Reports 21, 403–416, October 10, 2017hepatic ChREBP activity and not peripheral ChREBP is essential
for glucose-homeostasis maintenance. This result is consistent
with a previous study in which hepatic ChREBP overexpression
improved impaired glucose tolerance of high-fat-diet-chal-
lenged mice (Benhamed et al., 2012) and is in agreement
with a recent study reporting that liver Chrebp knockout mice
exhibit impaired insulin sensitivity and glucose intolerance (Jois
et al., 2017). In this study, while hepatic Chrebp deletion
protected against hepatic steatosis, it also resulted in gene
expression changes in white and brown adipose tissues,
suggesting inter-organ communication. The contribution of
ChREBP to whole-body energy balance may therefore rely on
its regulation of lipid species and/or hepatokine production
that could contribute to inter-tissue coordination of energy
homeostasis.
Activated in response to free fatty acids liberated from
adipocytes during fasting (Montagner et al., 2016), a role for he-
patocyte PPARa in the response to glucose had not yet been
identified. Our study reveals that the synergic induction of
Fgf21 by glucose and the PPARa agonist Wy-14643 occurs in
both mouse and human hepatocytes. We hypothesize that this
cross-talk is specific to Fgf21, as we found no effect of glucose
on other typical PPARa target genes. This Fgf21 specificity may
be due to the proximity of ChREBP- and PPARa-binding sites on
the Fgf21 proximal promoter, as both a PPRE and a ChoRE
region coexist (88 to 54 bp) (Girer et al., 2016). Microarray
analysis comparing gene regulation during fasting and glucose
challenge highlights a small subset of genes that are upregulated
in both conditions. Of those genes Fgf21 is the most significantly
induced. Therefore, FGF21 is a unique hepatic hormone showing
dual regulation by fasting and carbohydrate signaling. Few pub-
lications have proposed a dialog between ChREBP and PPARs
for the coordination of energy metabolism. Some examples of
cross-talk and regulatory mechanisms have been described for
lipid metabolism in brown adipose (Iizuka et al., 2013) and
pancreatic b cell function (Boergesen et al., 2011). In the liver,
it was also described that the PPARa co-factor PPAR g coacti-
vator-1b (PGC-1b) can act as a co-activator of ChREBP in
response to glucose. PGC-1b is known to activate genes
responsible for fatty acid oxidation and hepatic gluconeogenesis
during fasting (Vega et al., 2000; Yoon et al., 2001), and it was
also reported to upregulate de novo lipogenic genes during
glucose stimulation in a ChREBP-dependent manner (Chambers
et al., 2013). Altogether, these studies strongly suggest a direct
and/or indirect interaction between ChREBP and the PPAR
nuclear receptor family.
Here, we reveal a ChREBP-PPARa dialog in hepatocytes
required for the induction of Fgf21 by glucose. Indeed, despite
normal hepatic ChREBP activity toward glycolytic and lipogenic
genes, we report that in the absence of PPARa, ChREBP binding
to the Fgf21 ChoRE is significantly reduced, suggesting that
hepatocyte PPARa is necessary for the ChREBP-mediated
induction of Fgf21 in response to glucose. Our study also reports
that Fgf21 promoter accessibility is reduced in the absence of
PPARa. Deficient recruitment of ChREBP as well as Pol II was
observed at the proximal Fgf21 promoter locus under elevated
glucoseconditions in the liver ofmice lacking hepatocytePPARa.
The fact that epigenetic marks (i.e., H3K9ac) of active transcrip-
tion were reduced at the Fgf21 promoter when PPARawas lack-
ing in liver, under both fasting and glucose conditions, also sup-
ports the hypothesis of reduced promoter accessibility. Indeed,
evenunder conditionsofChREBPoverexpression,Fgf21expres-
sion was not efficiently induced in the context of PPARa defi-
ciency. Further experiments will be needed to determinewhether
PPARa acts as a ‘‘pioneer’’ transcription factor for Fgf21 tran-
scription. Among several described functions, pioneer factors
can trigger the opening and/or organization of the local chro-
matin, in turn allowing the binding of other transcription fac-
tors, histone-modification enzymes, chromatin modifiers, and/
or nucleosome remodelers (Zaret and Carroll, 2011). Of note,
an HDAC inhibitor potentiated a ChREBP-dependent effect
of glucose on Fgf21 expression in primary hepatocytes. The
HDAC inhibitor strategy in glucose-challenged PPARa-deficient
hepatocytes only led to a modest restoration of FgF21 expres-
sion.While this approachwas not sufficient to fully restore acces-
sibility to theFgf21promoter, it does suggest thatFgf21promoter
accessibility at the ChoRE is altered in the absence of PPARa
by a mechanism that may partly rely on histone acetylation. We
employed FAIRE-qPCR analysis to determine Fgf21 promoter
accessibility in response to glucose. A more sensitive approach,the assay for transposase-accessible chromatin with high-
throughput sequencing (ATAC-seq) (Buenrostro et al., 2013)
may have allowed us to determine whether Fgf21 promoter
accessibility is indeed modified by an HDAC inhibitor strategy
in Pparahep/ hepatocytes. While other molecular mechanisms
are clearly involved, the implication of specific HDACs should
be further investigated, since it was recently shown that PPARa
prevents the recruitment of HDAC3 to the Fgf21 promoter
in hepatocytes when concentrations of b-hydroxybutyrate, a
key product of b-oxidation, are elevated (Rando et al., 2016).
At the physiological level, we observed that Pparahep/mice
consumed more sucrose (+30%) than Pparahep+/+ mice. Two
studies have recently unraveled themechanistic link between su-
crose-derived FGF21 and nutrient preference (Talukdar et al.,
2016; von Holstein-Rathlou et al., 2016). FGF21 production in
response to carbohydrateswasshown tomarkedly reduce sweet
taste preference and suppress consumption of simple sugars by
acting on specific regions of the brain (Talukdar et al., 2016; von
Holstein-Rathlou et al., 2016). In these studies, hepatic FGF21
production in response to carbohydrate intake was attributed
to ChREBP activity. The fact that PPARa is also involved in this
liver-to-brain axis following simple sugar consumption opens
new molecular path of regulation of macronutrient preference/
intake and expands liver PPARa function from a fasting regulator
to a modulator affecting the physiological sugar response.
In conclusion, we identify a transcriptional node in the control
of hepatic FGF21 in response to glucose. The glucose sensor
ChREBP requires PPARa for the induction of FGF21 in response
to dietary sugar. This is a unique collaboration between tran-
scription factors that are activated in response to distinct
nutritional conditions (high glucose for ChREBP and fasting for
PPARa). These data imply that drug targeting of PPARa may
exert part of its beneficial effects on metabolic homeostasis by
supporting the ChREBP-induced loop controlling sweet prefer-
ence via FGF21.
EXPERIMENTAL PROCEDURES
Generation of ChREBP Knockout Mice
Mice lacking exons 9–15 of the Chrebp gene were generated through
homologous recombination. Correspondence regarding Chrebp/ mice
should be addressed to R.D. (renaud.dentin@inserm.fr) and C.P. (catherine.
postic@inserm.fr). Experimental details are provided in Supplemental
Experimental Procedures.
Animals
10- to 12-week-old adult male C57BL/6J, Chrebp+/+, Chrebp/, Pparahep+/+,
and Pparahep/ mice (Montagner et al., 2016) were used for all in vivo
experiments. For hepatocyte cultures, male and female mice were used as
described in the figure legends. Procedures were carried out according to
the French guidelines for the care and use of experimental animals (animal
authorization agreement number CEEA34.AFB/CP.082.12, Paris Descartes
Ethical Committee). Mice were maintained in a 12-hr light/dark cycle with
water and a standard diet (65% carbohydrate, 11% fat, and 24% protein)
unless otherwise specified. Nutritional challenges details are described in
Supplemental Experimental Procedures.
Injection of Adenovirus In Vivo
Adenovirus coding GFP and ChREBPCA (ChREBP isoform deleted of the LID
domain) (Li et al., 2006) produced by Laboratoire de the´rapie ge´nique (Nantes,
France; requests to R.D. at renaud.dentin@inserm.fr) were delivered throughCell Reports 21, 403–416, October 10, 2017 413
penis vein injection (3 3 109 [pfu]/mouse) to adult mice. Four days later,
nutritional protocols were applied.
Primary Cultures of Human and Mouse Hepatocytes
Human hepatocytes were prepared from lobectomy segments resected from
adult patients under the approval of the National Ethics Committee as
described previously (Pichard et al., 2006; Marmier et al., 2015). Mouse
hepatocytes were isolated as described previously (Dentin et al., 2004). Exper-
imental details regarding culture conditions are provided in the figure legends
and Supplemental Experimental Procedures.
ChIP Analysis
In vivo chromatin immunoprecipitation (ChIP) assays from mouse livers were
performed by Active Motif. Briefly, genomic DNA regions of interest were
isolated using antibodies against H3K9Ac (Active Motif), RNA Pol II (Active
Motif), ChREBP (Novus), and PPARa (Santa Cruz Biotechnology). qPCR
reactions were carried out in triplicate using SYBR Green Supermix (Bio-
Rad) on a CFX Connect Real Time PCR system. Positive and negative control
sites were tested for each factor as well as the sites of interest. The resulting
signals were normalized for primer efficiency by carrying out qPCR for each
primer pair using input DNA (pooled unprecipitated genomic DNA from each
sample). Specific enrichment was expressed as percentage of input. Further
details are provided in Supplemental Experimental Procedures.
In vitro ChIP assays from cultured hepatocytes were performed as
described previously (Marmier et al., 2015). Briefly, genomic DNA regions of
interest were isolated using antibodies against ChREBP (Novus) and immuno-
globulin G (IgG) (Cell Signaling). DNA fragments were quantified by qPCR us-
ing primers described in Table S1. Results are expressed as fold enrichment.
Further details are provided in Supplemental Experimental Procedures.
FAIRE-qPCR
FAIRE-qPCR was performed in Pparahep+/+ and Pparahep/ hepatocytes
using a protocol previously described (Simon et al., 2012). Briefly, cells were
treated with 1% formaldehyde at room temperature for 5 min to form DNA-
protein crosslinks, and the crosslinking was stopped by addition of glycine
to a final concentration of 125 mM. FAIRE was analyzed by qPCR on genomic
DNA using the ChoRE Fgf21 primers (Figure 5C) and calculated using relative
enrichment for each amplicon using the comparative Ct method, such that a
ratio is calculated for the signal from the FAIRE sample relative to the input
control DNA signal. Results are expressed as fold enrichment. Experimental
details are provided in Supplemental Experimental Procedures.
Gene Expression Analysis
Total cellular RNA was extracted using the SV total RNA isolation system
(Promega). For qPCR analysis, total RNA samples (2 mg) were reverse
transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). Primers for SYBR green assays are presented in Tables S2 and
S3. Primers used to measure Chrebp expression were designed to detect the
Chrebpa and Chrebpb isoforms. A specific primer to detect only the b isoform
was also used. Primers for Vnn1, Cyp4a10, and Cyp4a14 were previously
described (Montagner et al., 2016). Amplifications were performed on an
ABI Prism 7300 Real Time PCR System (Applied Biosystems). qPCR data
were normalized by TATA-box binding protein (TBP) mRNA levels or 18S ribo-
somal (18S) for human samples and analyzed with LinRegPCR.22.
Transcriptomic profiles were obtained using Agilent SurePrint G3 Mouse V2
GE 8x60K (Design 074809) following the manufacturer’s instructions. Data
were analyzed with R (http://www.r-project.org) using Bioconductor packages
(http://www.bioconductor.org, v 2.12; Gentleman et al., 2004) as described in
GEO: GSE26728. Amodel was fitted using the limma lmFit function (Wettenhall
and Smyth, 2004). Correction for multiple testing was applied using a
false discovery rate (Benjamini and Hochberg, 1995). Probes with adjusted
p % 0.05 were considered differentially expressed (n = 6). Hierarchical clus-
tering was applied and the differentially expressed probes using 1  Pearson
correlation coefficient as distance and Ward’s criterion for agglomeration. The
resulting dendrogram were illustrated as a heatmap. The enrichment of gene
ontology (GO) biological processes was evaluated using a conditional hyper-
geometric test (GOstats package; Falcon and Gentleman, 2007).414 Cell Reports 21, 403–416, October 10, 2017Western Blotting Analysis
Proteins from hepatocytes and liver tissue were extracted from whole-cell
lysates. Proteins were subjected to 10% SDS-PAGE gels and transferred
to nitrocellulose membranes. Rabbit polyclonal ChREBP (1:1,000, Novus
Biologicals) and L-PK (1:1,500, a gift from Dr. Axel Kahn) antibodies were
used. Protein b-actin (1:5,000) (Cell Signaling Technology) was used to
normalize data.
Analytical Analysis
Blood glucose was measured from total blood using an Accu-Check
glucometer (Roche). Liver triglycerides were measured with a colorimetric
diagnostic kit (Triglycerides FS, Diasys). Serum insulin concentrations were
determined using a rat insulin ELISA assay kit (Crystal Chem) with a mouse
insulin standard. The mouse ELISA kit (Millipore) was used to measure
FGF21 in cell culture medium (30 mL of medium was used) and mouse plasma
(20 mL).
Statistical Analysis
Data represent at least three independent experiments, are reported as
means ± SEM, and were analyzed with analysis of variance using Prism 5.0
(GraphPad) software. A Student’s t test was used when comparing two
groups (followed by Mann-Whitney post hoc test) or two-way ANOVA
when comparing three or more groups followed by a Bonferroni post hoc
test. Statistical significance was defined as p < 0.05.
DATA AND SOFTWARE AVAILABILITY
The accession number for the microarray data reported in this paper is GEO:
GSE92502.
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